Plasmid DNA
- High yield fermentation
- No enzymes or organic solvents
- Scalable production process
- Multi-gram capacity
- Direct injection or ex-vivo/further manufacturing applications
Recombinant protein
- Bacterial / mammalian hosts
- 30L fermentation / 50-250L mammalian cell culture
- Cell harvest by centrifuge or filtration
- Protein refolding
- Scalable downstream processing
Cell therapeutics
- Suspension / adherent manufacturing capabilities
- Large scale bioreactor / multi-tray production
- Vial / cryobag container formats
- Controlled cryopreservation
Viral vector/Vaccine
- Envelope / Non-envelope viruses
- DNA / RNA viruses
- 50-250L bioreactor / multi-tray formats
- Scalable chromatography and TFF
Microbial Vaccines/Therapeutics
- Custom development of high yield fermentation
- Harvest/wash by TFF
- Experience with aseptic process simulation of full manufacturing process
Aseptic fill/finish
- Fully-automated dispensing / capping
- ISO 2R/6R/10R vial formats
- 2,000 unit capacity
- Prior media fill simulations and container closure integrity with annual requalification
Your Industry-Academia Hybrid CDMO
Strategically part of the University of Wisconsin-Madison, WB maintains industry-standard facilities, equipment, and quality systems with a scientific staff that provide a highly flexible and collaborative project management approach. WB has a proven track record for producing high-quality clinical trial material for both large and small biotech companies, universities, and federal agencies for regulatory filings in the US and other global markets.
Waisman Biomanufacturing has manufactured hundreds of clinical grade products since inception in 2001 and has earned a reputation as a strategic partner for cost effective and timely delivery. We strive to meet these high standards with each manufacturing campaign or development program.